Business Context and Reporting Period
Company: Aldeyra Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2014
Context: The filing reports corporate governance actions taken in connection with the completion of the Company's initial public offering (IPO).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on legal and corporate structural updates.
Material Changes
- Restated Certificate of Incorporation: Filed with the Secretary of State of Delaware on May 6, 2014.
- Amended and Restated Bylaws: Adopted on May 6, 2014.
- Approval: Both documents were previously approved by the Board of Directors to facilitate the IPO.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. Details regarding the capital stock described in the Restated Certificate and Bylaws are incorporated by reference to the Registration Statement on Form S-1 (File No. 333-193204) filed on May 1, 2014.
Investor Verification Checklist
- Verify the specific provisions of the Restated Certificate of Incorporation and Amended and Restated Bylaws by reviewing Exhibits 3.1 and 3.2 attached to this filing.
- Review the "Description of Capital Stock" section (pages 105-109) of the Form S-1 filed on May 1, 2014, for detailed terms of the equity structure.
- Confirm the status of the IPO completion referenced in the filing.